Drug Eluting Stent Market: Market Size & Forecast 2026

Drug-eluting stents are small, expandable tubes made of metal or polymer that are inserted into coronary or peripheral arteries to keep them open following angioplasty. Unlike bare-metal stents, DES devices are coated with antiproliferative drugs such as sirolimus, paclitaxel, or everolimus that are released locally to inhibit scar tissue formation and restenosis. The global DES market encompasses both coronary and peripheral vascular applications, with coronary stenting representing the largest application segment due to the high prevalence of coronary artery disease worldwide.

• •Technology originated in the early 2000s and has largely replaced bare-metal stents in developed markets due to superior clinical outcomes
• •Current generation stents feature thinner struts, improved biocompatible polymers, and enhanced drug delivery profiles
• •Regulatory approval pathways vary by region, with FDA, CE Mark, and NMPA (China) representing key certification bodies

The rising global burden of cardiovascular diseases, driven by sedentary lifestyles, poor dietary habits, and aging populations, remains the primary growth catalyst for the DES market. Technological advancements including thinner stent struts, bioresorbable scaffolds, and polymer-free coatings have improved safety profiles and expanded clinical indications. Additionally, the growing preference for minimally invasive procedures over open-heart surgery, coupled with improving healthcare infrastructure in emerging markets, is fueling demand.

• •Cardiovascular diseases account for approximately 17.9 million deaths annually worldwide, creating a large and growing patient pool requiring interventional treatment
• •Second- and third-generation DES platforms with improved deliverability and reduced thrombosis risk have driven higher adoption rates among interventional cardiologists
• •Economic growth in Asia-Pacific and Latin America is expanding access to advanced cardiac care, particularly in China and India

The DES market is segmented by type into coronary stenting and peripheral arterial stenting, with coronary applications representing the dominant share. Product differentiation occurs through coating type, including polymer-based first- and second-generation coatings, polymer-free coatings, and bioabsorbable polymer platforms, each offering distinct clinical trade-offs between efficacy and safety. Geographically, North America and Europe currently lead in market value due to high procedure volumes and favorable reimbursement frameworks, while the Asia-Pacific region is emerging as the fastest-growing market.

• •Polymer-based coatings currently dominate the market, though polymer-free and bioabsorbable polymer technologies are gaining share based on clinical safety data
• •North America represents the largest regional market, while Asia-Pacific is projected to grow at the fastest rate due to rising disease prevalence and healthcare investment
• •Peripheral vascular applications, though smaller than coronary, are expanding as DES technology is adapted for treating peripheral artery disease in lower limbs

What are the recent trends and outlook?

The DES market is expected to continue evolving toward more sophisticated platform technologies that balance anti-restenotic efficacy with long-term biocompatibility. Bioresorbable vascular scaffolds, drug-coated balloons, and fully absorbable stents represent areas of active research and clinical investigation, though these technologies currently occupy smaller market niches. Market growth will likely be sustained by the ongoing transition toward next-generation DES platforms in developed regions, combined with first-time stent adoption in underserved emerging markets.

• •Investment in bioabsorbable polymer and polymer-free stent technologies is accelerating as clinicians seek to eliminate long-term polymer-related complications
• •Value-based healthcare models and comparative effectiveness research are influencing physician device selection and hospital procurement decisions
• •Expansion of indications to include left main coronary artery disease, chronic total occlusions, and peripheral vascular disease will broaden the addressable patient population through 2030 and beyond